When GLP-1s became popular for weight loss, the market saw a shortage of them, which is why the FDA allowed compounding pharmacies to begin formulating non-branded, compounded versions of them
Several GLP-1RAs, including semaglutide, have been shown to offer cardiovascular outcome benefit in people with T2D 33,34,35
The consumption of a high-fat diet (HFD) is strongly associated with this condition, leading to visceral obesity and insulin resistance, which can cause neurological issues such as anxiety and depression [3, 4] and may even contribute to the progression of Alzheimer's and Parkinsons disease [5, 6]
In clinical studies, Semaglutide is shown to help patients lose an average of 20% weight*
It might